Experimental drug for Post-Transplant lung disease shows early safety signals
NCT ID NCT04239989
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 24 times
Summary
This early-stage study tested the safety of a drug called itacitinib in 8 adults who developed bronchiolitis obliterans syndrome (a type of lung scarring) after a donor stem cell transplant. The drug works by blocking certain enzymes that may contribute to lung damage. The study was stopped early, but researchers monitored side effects and lung function changes to see if the drug could help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIOLITIS OBLITERANS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.